Karyopharm secures $100 million financing, extends cash runway into 2026, projects $42 million–$44 million Q3 revenue, and advances Phase 3 selinexor trial.
Karyopharm secures $100 million financing, extends cash runway into 2026, projects $42 million–$44 million Q3 revenue, and advances Phase 3 selinexor trial.
Copyright © Louis Velazquez. All Rights Reserved.